An urgent need for standardization of stem cells and stem cell-derived products toward clinical applications.
作者信息
Lappin Terry, Cheng Tao
机构信息
Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, Northern Ireland, UK.
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, People's Republic of China.
出版信息
Stem Cells Transl Med. 2021 Nov;10 Suppl 2(Suppl 2):S1-S3. doi: 10.1002/sctm.21-0269.
Abstract
摘要
相似文献
1
An urgent need for standardization of stem cells and stem cell-derived products toward clinical applications.迫切需要对干细胞及干细胞衍生产品进行标准化，以用于临床应用。
Stem Cells Transl Med. 2021 Nov;10 Suppl 2(Suppl 2):S1-S3. doi: 10.1002/sctm.21-0269.
2
Redefining the concept of standardization for pluripotent stem cells.重新定义多能干细胞标准化的概念。
Stem Cell Rev Rep. 2011 Jun;7(2):221-6. doi: 10.1007/s12015-010-9204-8.
3
ISO/TC 249 platform promotes the development of international standardization and trade for the Chinese medicines industry.ISO/TC 249平台推动中药行业的国际标准化和贸易发展。
Pharmacol Res. 2020 Oct;160:105066. doi: 10.1016/j.phrs.2020.105066. Epub 2020 Jul 7.
4
Current practices and prospects for standardization of the hematopoietic colony-forming unit assay: a report by the cellular therapy team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative.现行的造血集落形成单位检测标准化实践和前景：来自生物医学卓越输血安全（BEST）协作的细胞治疗小组的报告。
Cytotherapy. 2013 Mar;15(3):255-62. doi: 10.1016/j.jcyt.2012.11.013.
5
Harmonization and standardization of immunogenicity assessment of biotherapeutic products.生物治疗产品免疫原性评估的协调与标准化。
Bioanalysis. 2019 Sep;11(17):1593-1604. doi: 10.4155/bio-2019-0202.
6
Establishing standards for the characterization of human embryonic stem cell lines.建立人类胚胎干细胞系特性鉴定的标准。
Stem Cells. 2006 Jan;24(1):145-50. doi: 10.1634/stemcells.2005-0432. Epub 2005 Oct 27.
7
Standardization as situation-specific achievement: regulatory diversity and the production of value in intercontinental collaborations in stem cell medicine.作为特定情境下成果的标准化：监管多样性与干细胞医学洲际合作中的价值创造
Soc Sci Med. 2014 Dec;122:72-80. doi: 10.1016/j.socscimed.2014.10.018. Epub 2014 Oct 7.
8
Setting standards for stem cells.为干细胞设定标准。
Nat Methods. 2023 Sep;20(9):1267. doi: 10.1038/s41592-023-02016-5.
9
[Research on the Standardization System of Diagnosis Products at Home and Abroad].国内外诊断产品标准化体系研究
Zhongguo Yi Liao Qi Xie Za Zhi. 2018 Sep 30;42(5):361-364. doi: 10.3969/j.issn.1671-7104.2018.05.014.
10
Standardization of Quantitative DCE-MRI Parameters Measurement: An Urgent Need for Breast Cancer Imaging.定量动态对比增强磁共振成像（DCE-MRI）参数测量的标准化：乳腺癌成像的迫切需求。
Acad Radiol. 2022 Jan;29 Suppl 1:S87-S88. doi: 10.1016/j.acra.2021.12.002. Epub 2022 Jan 3.
引用本文的文献
1
Adipose-derived mesenchymal stromal/stem cells in type 1 diabetes treatment.1型糖尿病治疗中的脂肪来源间充质基质/干细胞
Commun Biol. 2025 Jul 23;8(1):1094. doi: 10.1038/s42003-025-08244-z.
2
Stem Cell Therapy for Diseases of Livestock Animals: An In-Depth Review.家畜疾病的干细胞疗法：深入综述
Vet Sci. 2025 Jan 17;12(1):67. doi: 10.3390/vetsci12010067.
3
Evaluation of the Precision of Kinetic Stem Cell (KSC) Counting for Specific Quantification of Human Mesenchymal Stem Cells in Heterogeneous Tissue Cell Preparations.评估动力学干细胞（KSC）计数在异质性组织细胞制剂中对人骨髓间充质干细胞进行特异性定量的精度。
Life (Basel). 2023 Dec 28;14(1):51. doi: 10.3390/life14010051.
本文引用的文献
1
Understanding the "SMART" features of hematopoietic stem cells and beyond.理解造血干细胞的“SMART”特性及其他特性。
Sci China Life Sci. 2021 Dec;64(12):2030-2044. doi: 10.1007/s11427-021-1961-1. Epub 2021 Jul 30.
2
ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update.国际干细胞研究学会干细胞研究与临床转化指南：2021 年更新版。
Stem Cell Reports. 2021 Jun 8;16(6):1398-1408. doi: 10.1016/j.stemcr.2021.05.012. Epub 2021 May 27.
3
Regulated, reliable, and reputable: Protect patients with uniform standards for stem cell treatments.规范、可靠、值得信赖：采用统一标准保护干细胞治疗的患者。
Stem Cells Transl Med. 2020 May;9(5):547-553. doi: 10.1002/sctm.19-0377. Epub 2020 Feb 10.
4
Clinical Translation of Pluripotent Stem Cell Therapies: Challenges and Considerations.多能干细胞疗法的临床转化：挑战与考量。
Cell Stem Cell. 2019 Nov 7;25(5):594-606. doi: 10.1016/j.stem.2019.10.001.
5
Stem Cells in the Treatment of Disease.干细胞在疾病治疗中的应用
N Engl J Med. 2019 May 2;380(18):1748-1760. doi: 10.1056/NEJMra1716145.
6
Marketing of unproven stem cell-based interventions: A call to action.未经证实的基于干细胞的干预措施的营销：行动呼吁。
Sci Transl Med. 2017 Jul 5;9(397). doi: 10.1126/scitranslmed.aag0426.
7
Stem cell science on the rise in China.中国干细胞科学研究方兴未艾。
Cell Stem Cell. 2012 Jan 6;10(1):12-5. doi: 10.1016/j.stem.2011.12.002.
8
FDA regulation of stem cell-based products.美国食品药品监督管理局对基于干细胞的产品的监管。
Science. 2009 Jun 26;324(5935):1662-3. doi: 10.1126/science.1173712.
9
Stem-cell-derived products: an FDA update.干细胞衍生产品：美国食品药品监督管理局的最新情况
Trends Pharmacol Sci. 2008 Dec;29(12):591-3. doi: 10.1016/j.tips.2008.09.003. Epub 2008 Oct 18.
10
Toward 'SMART' stem cells.迈向“智能”干细胞。
Gene Ther. 2008 Jan;15(2):67-73. doi: 10.1038/sj.gt.3303066. Epub 2007 Nov 29.
Zotero 插件